Talphera (TLPH) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Document Information [Line Items]
Entity Central Index Key	0001427925
Entity Registrant Name	ACELRX PHARMACEUTICALS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-35068
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-2193603
Entity Address, Address Line One	25821 Industrial Boulevard, Suite 400
Entity Address, City or Town	Hayward
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94545
City Area Code	650
Local Phone Number	216-3500
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ACRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		147,114,006

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 21,822	$ 12,663	[1]
Short-term investments	17,527	38,967	[1]
Accounts receivable, net	184	160	[1]
Inventories, net	1,045	1,111	[1]
Prepaid expenses and other current assets	2,233	2,588	[1]
Total current assets	42,811	55,489	[1]
Operating lease right-of-use assets	4,147	4,302	[1]
Property and equipment, net	15,933	15,928	[1]
In-process research and development asset	8,819	0
Other assets	261	2,174	[1]
Total Assets	71,971	77,893	[1]
Current Liabilities:
Accounts payable	2,715	2,121	[1]
Accrued and other liabilities	4,321	6,524	[1]
Long-term debt, current portion	8,813	8,796	[1]
Operating lease liabilities, current portion	1,184	1,068	[1]
Total current liabilities	17,033	18,509	[1]
Long-term debt, net of current portion	3,041	5,007	[1]
Deferred revenue, net of current portion	1,122	1,151
Operating lease liabilities, net of current portion	3,578	3,750	[1]
Liability related to the sale of future royalties	84,615	85,288	[1]
Other long-term liabilities	855	81	[1]
Total liabilities	110,244	113,786	[1]
Commitments and Contingencies
Stockholders’ Deficit:
Common stock, $0.001 par value—200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 147,109,007 and 136,819,647 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	147	137	[1]
Additional paid-in capital	443,838	437,554	[1]
Accumulated deficit	(482,258)	(473,584)	[1]
Total stockholders’ deficit	(38,273)	(35,893)	[1]
Total Liabilities and Stockholders’ Deficit	$ 71,971	$ 77,893	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	147,109,007	136,819,647
Common stock, shares outstanding (in shares)	147,109,007	136,819,647

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue:
Revenue	$ 442	$ 511
Operating costs and expenses:
Cost of goods sold	784	1,040
Research and development	1,315	969
Selling, general and administrative	7,338	7,644
Total operating costs and expenses	9,437	9,653
Loss from operations	(8,995)	(9,142)
Other income:
Interest expense	(390)	(672)
Interest income and other income, net	38	76
Non-cash interest income on liability related to future sale of royalties	673	782
Total other income	321	186
Net loss	$ (8,674)	$ (8,956)
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.06)	$ (0.08)
Shares used in computing net loss per share of common stock, basic and diluted – See Note 11 (in shares)	145,623,751	113,256,550
Product [Member]
Revenue:
Revenue	$ 442	$ 451
Contract and Other Collaboration [Member]
Revenue:
Revenue	$ 0	$ 60

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2020	98,812,008
Balance at Dec. 31, 2020	$ 98	$ 382,637	$ (438,485)	$ (55,750)
Stock-based compensation	$ 0	1,089	0	1,089
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares)	404,172
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes	$ 0	(249)	0	(249)
Issuance of common stock upon ESPP purchase (in shares)	183,132
Issuance of common stock upon ESPP purchase	$ 0	192	0	192
Net loss	$ 0	0	(8,956)	(8,956)
Net proceeds from issuance of common stock in connection with equity financings (in shares)	19,701,562
Net proceeds from issuance of common stock in connection with equity financings	$ 20	36,340	0	36,360
Issuance of common stock upon exercise of stock options (in shares)	2,125
Issuance of common stock upon exercise of stock options	$ 0	2	0	2
Balance (in shares) at Mar. 31, 2021	119,102,999
Balance at Mar. 31, 2021	$ 118	420,011	(447,441)	(27,312)
Balance (in shares) at Dec. 31, 2021	136,819,647
Balance at Dec. 31, 2021	$ 137	437,554	(473,584)	(35,893)	[1]
Stock-based compensation	$ 0	783	0	783
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes (in shares)	515,393
Issuance of common stock upon vesting of restricted stock units, net of shares withheld for employee taxes	$ 0	(58)	0	(58)
Issuance of common stock in connection with asset acquisition (in shares)	9,620,532
Issuance of common stock in connection with asset acquisition	$ 10	5,501	0	5,511
Issuance of common stock upon ESPP purchase (in shares)	153,435
Issuance of common stock upon ESPP purchase	$ 0	58	0	58
Net loss	$ 0	0	(8,674)	$ (8,674)
Issuance of common stock upon exercise of stock options (in shares)				0
Balance (in shares) at Mar. 31, 2022	147,109,007
Balance at Mar. 31, 2022	$ 147	$ 443,838	$ (482,258)	$ (38,273)
[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (8,674)	$ (8,956)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to royalty monetization	0	(45)
Non-cash interest income on liability related to royalty monetization	(673)	(782)
Depreciation and amortization	420	450
Non-cash interest expense related to debt financing	134	222
Stock-based compensation	783	1,089
Gain on lease termination	0	(522)
Other	2	68
Changes in operating assets and liabilities:
Accounts receivable	(24)	(23)
Inventories	57	105
Prepaid expenses and other assets	360	361
Accounts payable	249	313
Accrued liabilities	(1,512)	(1,698)
Operating lease liabilities	(56)	(241)
Deferred revenue	0	(49)
Net cash used in operating activities	(8,934)	(9,708)
Cash flows from investing activities:
Purchase of property and equipment	(89)	(24)
Purchase of investments	(6,175)	(24,441)
Cash paid for asset acquisition, net of cash acquired	(1,156)	0
Proceeds from maturities of investments	27,596	7,040
Net cash provided by (used in) investing activities	20,176	(17,425)
Cash flows from financing activities:
Payment of long-term debt	(2,083)	(2,083)
Net proceeds from issuance of common stock in connection with equity financings	0	36,360
Net proceeds from issuance of common stock through equity plans	58	194
Payment of employee tax obligations related to vesting of restricted stock units	(58)	(249)
Net cash (used in) provided by financing activities	(2,083)	34,222
Net increase in cash and cash equivalents	9,159	7,089
Cash and cash equivalents—Beginning of period	12,663	27,274
Cash and cash equivalents—End of period	21,822	34,363
NONCASH INVESTING ACTIVITIES:
Purchases of property and equipment in accounts payable and accrued liabilities	1,275	1,678
Asset acquisition costs in accounts payable and accrued liabilities	531	0
Liability for hold back shares in connection with asset acquisition in other long-term liabilities	800	0
Issuance of common stock in connection with asset acquisition	$ 5,511	$ 0

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. The Company AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, May 12, 2021 ( Termination of Gr nenthal Agreements July 2021, 10 3 10 50 January 7, 2022, November 14, 2021, 4. not second 608, The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of March 31, 2022, one 10 September 18, 2015, August 31, 2020, third Termination of Gr nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021. Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three March 31, 2022, not may December 31, 2022, December 31, 2021, December 31, 2021, 10 March 10, 2022. 10 December 31, 2021, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not Significant Accounting Policies The Company’s significant accounting policies are detailed in its Annual Report on Form 10 December 31, 2021. no three March 31, 2022, 2021 10 Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not first not, not Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not not no may not Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. January 2021, 2021 01, Reference Rate Reform (Topic 848 848 2020 04.

Note 2 - Investments and Fair V

Note 2 - Investments and Fair Value Measurement	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Investments and Fair Value Measurement Disclosure [Text Block]	2. Investments The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond one The table below summarizes the Company’s cash, cash equivalents and short-term investments (in thousands): As of March 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 2,621 $ — $ — $ 2,621 Money market funds 562 — — 562 Commercial paper 18,639 — — 18,639 Total cash and cash equivalents 21,822 — — 21,822 Short-term investments: Commercial paper 13,557 — — 13,557 Corporate debt securities 3,970 — — 3,970 Total short-term investments 17,527 — — 17,527 Total cash, cash equivalents and short-term investments $ 39,349 $ — $ — $ 39,349 As of December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 1,443 $ — $ — $ 1,443 Money market funds 2,822 — — 2,822 Commercial paper 8,398 — — 8,398 Total cash and cash equivalents 12,663 — — 12,663 Short-term investments: Commercial paper 29,504 — — 29,504 Corporate debt securities 9,463 — — 9,463 Total short-term investments 38,967 — — 38,967 Total cash, cash equivalents and short-term investments $ 51,630 $ — $ — $ 51,630 There were no other-than-temporary impairments for these securities at March 31, 2022 December 31, 2021. no three March 31, 2022 2021. As of March 31, 2022, December 31, 2021, one Fair Value Measurement The Company’s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 third March 31, 2022, December 31, 2021, 6 two The following table sets forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands): As of March 31, 2022 Fair Value Level I Level II Level III Assets Money market funds $ 562 $ 562 $ — $ — Commercial paper 32,196 — 32,196 — Corporate debt securities 3,970 — 3,970 — Total assets measured at fair value $ 36,728 $ 562 $ 36,166 $ — Liabilities Contingent put option liability $ 55 $ — $ — $ 55 Total liabilities measured at fair value $ 55 $ — $ — $ 55 As of December 31, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 2,822 $ 2,822 $ — $ — Commercial paper 37,902 — 37,902 — Corporate debt securities 9,463 — 9,463 — Total assets measured at fair value $ 50,187 $ 2,822 $ 47,365 $ — Liabilities Contingent put option liability $ 81 $ — $ — $ 81 Total liabilities measured at fair value $ 81 $ — $ — $ 81 The following tables set forth a summary of the changes in the fair value of the Company’s Level III financial liabilities for the three March 31, 2022 2021 Three Months Ended March 31, 2022 Fair value—beginning of period $ 81 Change in fair value of contingent put option associated with the Loan Agreement (26 ) Fair value—end of period $ 55 Three Months Ended March 31, 2021 Fair value—beginning of period $ 246 Change in fair value of contingent put option associated with the Loan Agreement (65 ) Fair value—end of period $ 181 There were no transfers between Level I, Level II or Level III of the fair value hierarchy during the three March 31, 2022 December 31, 2021.

Note 3 - Inventories, Net

Note 3 - Inventories, Net	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or net realizable value and consist of the following (in thousands): Balance as of March 31, 2022 December 31, 2021 Raw materials $ 651 $ 722 Work-in-process 35 159 Finished goods 359 230 Total $ 1,045 $ 1,111 The Company did not three March 31, 2022. three March 31, 2021.

Note 4 - Asset Acquisition

Note 4 - Asset Acquisition	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Business Combination Disclosure [Text Block]	4. On January 7, 2022, five January 7, 2022, The shares issued pursuant to the Merger Agreement were issued in private placements pursuant to the exemption from registration under Section 4 2 1933, 506 not The Merger Agreement has been accounted for as an asset acquisition of a single IPR&D asset that has an alternative future use. The initial measurement of the asset purchased of $8.8 million was based on the purchase cost of $12.4 million including (i) $6.0 million common stock fair value on the closing date (issued and hold back on the acquisition date), (ii) $0.5 million seller’s costs paid by the Company, (iii) $3.5 million cash and (iv) approximately $2.5 million of transaction costs less purchase price allocated to cash acquired of $3.5 million. Due to the nature of regulatory and sales-based milestones, the contingent consideration of up to $26.0 million was not not March 31, 2022, none The following table summarizes the total consideration for the acquisition and the value of the IPR&D asset acquired (in thousands): Consideration Cash $ 3,536 Issuance of common stock to Lowell security holders in connection with asset acquisition 5,161 Issuance of common stock to settle Lowell’s transaction costs in connection with asset acquisition 350 Liability for issuance of 1,396,526 (1) 800 Transaction costs 2,521 Total consideration $ 12,368 IPR&D Asset Acquired Purchase price $ 12,368 Cash acquired (3,549 ) Total IPR&D asset acquired (2) $ 8,819 ( 1 ( 2 The IPR&D asset will be treated initially as an indefinite-lived asset, and as a long-lived asset, it will be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not

Note 5 - Revenue From Contracts

Note 5 - Revenue From Contracts With Customers	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	5. The following table summarizes revenue from contracts with customers for the three March 31, 2022 2021 Three Months Ended March 31, 2022 2021 Product sales: DSUVIA $ 442 $ 181 Zalviso — 270 Total product sales 442 451 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 8) — 45 Royalty revenue — 15 Total revenues from contract and other collaboration — 60 Total revenue $ 442 $ 511 For additional details on the Company’s accounting policy regarding revenue recognition, refer to Note 1 10 December 31, 2021. Product Sales The Company’s commercial launch of DSUVIA in the United States occurred in the first 2019. May 12, 2021. not March 31, 2022. Contract and Other Collaboration Contract and other collaboration revenue includes revenue under the Grünenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe and license revenue recognized under the DZUVEO Agreement. For the three March 31, 2022, not Contract Liabilities A contract liability of $1.2 million was recorded on the Condensed Consolidated Balance Sheets as deferred revenue as of March 31, 2022, not The following table presents changes in the Company’s contract liability for the three March 31, 2022 2021 Balance at January 1, 2022 $ 1,237 Deductions for performance obligations satisfied: In current period — Balance at March 31, 2022 $ 1,237 Balance at January 1, 2021 $ 49 Deductions for performance obligations satisfied: In current period (49 ) Balance at March 31, 2021 $ —

Note 6 - Long-term Debt

Note 6 - Long-term Debt	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Long-Term Debt [Text Block]	6. Loan Agreement with Oxford On May 30, 2019, May 30, 2019. In connection with the Loan Agreement, on May 30, 2019, As of March 31, 2022 December 31, 2021, three March 31, 2022, three March 31, 2021. Non-Interest Bearing Payments for the Construction of Leasehold Improvements In August 2019, may four July 2022. March 31, 2022 December 31, 2021, March 31, 2022

Note 7 - Leases

Note 7 - Leases	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	7. Office Lease On March 26, 2021, 25821 April 1, 2021. two three one Contract Manufacturing Leases The Company has entered into commercial supply manufacturing services agreements related to Zalviso and DSUVIA containing fixed fees which it has determined are in-substance lease payments. For additional information on these agreements, refer to Note 9 10 December 31, 2021. The components of lease expense are presented in the following table (in thousands): Three Months Ended March 31, 2022 2021 Operating lease costs $ 343 $ 340 Gain on derecognition of operating lease — (522 ) Sublease income — (150 ) Net lease costs $ 343 $ (332 ) The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table: March 31, 2022 March 31, 2021 Weighted-average remaining lease term – operating leases (in years) 4.74 0.57 Weighted-average remaining discount rate – operating leases 12.8 % 12.03 % Maturities of lease liabilities as of March 31, 2022 Year: 2022 $ 1,363 2023 1,294 2024 1,040 2025 1,040 2026 1,040 Thereafter 415 Total future minimum lease payments 6,192 Less imputed interest (1,430 ) Total $ 4,762 Reported as: Operating lease liabilities $ 4,762 Operating lease liabilities, current portion (1,184 ) Operating lease liabilities, net of current portion $ 3,578

Note 8 - Liability Related to S

Note 8 - Liability Related to Sale of Future Royalties	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Liability Related To Sale Of Future Royalties Disclosure [Text Block]	8. On September 18, 2015, first four 80% $195.0 The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company’s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the three June 30, 2020, November 13, 2020. May 12, 2021 May 12, 2021. may The effective interest rate over the life of the liability will be 0% as the Company records interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rate for the three March 31, 2022 2021, The following table shows the activity within the liability account for the three September 18, 2015 March 31, 2022 ( Three months ended March 31, 2022 Period from inception to March 31, 2022 Liability related to sale of future royalties — beginning balance $ 85,288 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue — (1,083 ) Non-cash interest (income) expense recognized (673 ) 24,514 Liability related to sale of future royalties as of March 31, 2022 $ 84,615 $ 84,615 As royalties are remitted to SWK from ARPI LLC, as described in Note 1 10 December 31, 2021,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Litigation On June 8, 2021, two 10 20 10b 5 December 16, 2021, March 7, 2022. three 10 20 10b 5 20A May 6, 2022. On July 6, 2021, September 30, 2021, October 26, 2021, November 17, 2021, three nine four December 6, 2021, four 1A. may . The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that may

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	10. The Company recorded total stock-based compensation expense for stock options, restricted stock units, or RSUs, and the Amended and Restated 2011 March 31, 2022 March 31, 2021 Cost of goods sold $ 19 $ 22 Research and development 174 181 Selling, general and administrative 590 886 Total $ 783 $ 1,089 The following table summarizes restricted stock unit activity under the Company’s equity incentive plans: Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2022 1,774,376 $ 1.71 Granted 1,061,826 0.40 Vested (657,359 ) 1.92 Forfeited (145,838 ) 1.56 Restricted stock units outstanding, March 31, 2022 2,033,005 $ 0.97 Upon vesting, certain of the Company’s RSUs may March 31, 2022, The following table summarizes stock option activity under the Company’s equity incentive plans: Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) January 1, 2022 14,284,050 $ 2.99 Granted 2,123,650 0.40 Forfeited (248,334 ) 1.72 Expired (517,902 ) 3.20 Exercised — — March 31, 2022 15,641,464 $ 2.65 6.2 $ — Vested and exercisable options—March 31, 2022 10,426,287 $ 3.36 4.8 $ — Vested and expected to vest—March 31, 2022 15,641,464 $ 2.65 6.2 $ — The per-share weighted average grant date fair value of the options granted during the quarter ended March 31, 2022 Three months ended March 31, 2022 Expected term (in years) 6.3 Risk-free interest rate 1.6% - 2.2% Expected volatility 88% Expected dividend rate 0% As of March 31, 2022,

Note 11 - Net Loss Per Share of

Note 11 - Net Loss Per Share of Common Stock	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	11. The Company’s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, RSUs, and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: Three Months Ended March 31, 2022 2021 ESPP, RSUs and stock options to purchase common stock 17,864,469 16,789,212 Common stock warrants 17,676,679 176,679 In addition, the shares held back and contingently issuable in connection with the Lowell Merger, as described in Note 4. not

Note 12 - Subsequent Event

Note 12 - Subsequent Event	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	12. May 2022, second 2022. may may not may

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Business Description of Entity [Policy Text Block]	The Company AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on July 13, 2005 AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA® November 2, 2018, first 2019. June 2018, not may one July 2021, May 12, 2021 ( Termination of Gr nenthal Agreements July 2021, 10 3 10 50 January 7, 2022, November 14, 2021, 4. not second 608, The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of March 31, 2022, one 10 September 18, 2015, August 31, 2020, third Termination of Gr nenthal Agreements On December 16, 2013, July 17, 2015 September 20, 2016, 28 September 2015, December 16, 2013, July 22, 2015, July 17, 2015. On May 18, 2020, November 13, 2020. May 12, 2021 May 12, 2021.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the rules and regulations of the United States. Securities and Exchange Commission, or SEC. Accordingly, they do not Operating results for the three March 31, 2022, not may December 31, 2022, December 31, 2021, December 31, 2021, 10 March 10, 2022. 10 December 31, 2021,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
Business Combinations Policy [Policy Text Block]	Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not first not, not Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not not no may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In June 2016, 2016 13, Financial Instruments Credit Losses: Measurement of Credit Losses on Financial Instruments, 2016 13. 2016 13 2016 13 January 1, 2023, January 1, 2020. May 2019, 2019 05, Financial Instruments Credit Losses, 2019 05, 2016 13. 2016 13 2019 05 not In March 2020, 2020 04, Reference Rate Reform (Topic 848 may December 31, 2022. January 2021, 2021 01, Reference Rate Reform (Topic 848 848 2020 04.

Note 2 - Investments and Fair_2

Note 2 - Investments and Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Cash, Cash Equivalents and Investments [Table Text Block]	As of March 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 2,621 $ — $ — $ 2,621 Money market funds 562 — — 562 Commercial paper 18,639 — — 18,639 Total cash and cash equivalents 21,822 — — 21,822 Short-term investments: Commercial paper 13,557 — — 13,557 Corporate debt securities 3,970 — — 3,970 Total short-term investments 17,527 — — 17,527 Total cash, cash equivalents and short-term investments $ 39,349 $ — $ — $ 39,349 As of December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and cash equivalents: Cash $ 1,443 $ — $ — $ 1,443 Money market funds 2,822 — — 2,822 Commercial paper 8,398 — — 8,398 Total cash and cash equivalents 12,663 — — 12,663 Short-term investments: Commercial paper 29,504 — — 29,504 Corporate debt securities 9,463 — — 9,463 Total short-term investments 38,967 — — 38,967 Total cash, cash equivalents and short-term investments $ 51,630 $ — $ — $ 51,630
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	As of March 31, 2022 Fair Value Level I Level II Level III Assets Money market funds $ 562 $ 562 $ — $ — Commercial paper 32,196 — 32,196 — Corporate debt securities 3,970 — 3,970 — Total assets measured at fair value $ 36,728 $ 562 $ 36,166 $ — Liabilities Contingent put option liability $ 55 $ — $ — $ 55 Total liabilities measured at fair value $ 55 $ — $ — $ 55 As of December 31, 2021 Fair Value Level I Level II Level III Assets Money market funds $ 2,822 $ 2,822 $ — $ — Commercial paper 37,902 — 37,902 — Corporate debt securities 9,463 — 9,463 — Total assets measured at fair value $ 50,187 $ 2,822 $ 47,365 $ — Liabilities Contingent put option liability $ 81 $ — $ — $ 81 Total liabilities measured at fair value $ 81 $ — $ — $ 81
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended March 31, 2022 Fair value—beginning of period $ 81 Change in fair value of contingent put option associated with the Loan Agreement (26 ) Fair value—end of period $ 55 Three Months Ended March 31, 2021 Fair value—beginning of period $ 246 Change in fair value of contingent put option associated with the Loan Agreement (65 ) Fair value—end of period $ 181

Note 3 - Inventories, Net (Tabl

Note 3 - Inventories, Net (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	Balance as of March 31, 2022 December 31, 2021 Raw materials $ 651 $ 722 Work-in-process 35 159 Finished goods 359 230 Total $ 1,045 $ 1,111

Note 4 - Asset Acquisition (Tab

Note 4 - Asset Acquisition (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Consideration Cash $ 3,536 Issuance of common stock to Lowell security holders in connection with asset acquisition 5,161 Issuance of common stock to settle Lowell’s transaction costs in connection with asset acquisition 350 Liability for issuance of 1,396,526 (1) 800 Transaction costs 2,521 Total consideration $ 12,368 IPR&D Asset Acquired Purchase price $ 12,368 Cash acquired (3,549 ) Total IPR&D asset acquired (2) $ 8,819

Note 5 - Revenue From Contrac_2

Note 5 - Revenue From Contracts With Customers (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2022 2021 Product sales: DSUVIA $ 442 $ 181 Zalviso — 270 Total product sales 442 451 Contract and other collaboration: Non-cash royalty revenue related to Royalty Monetization (See Note 8) — 45 Royalty revenue — 15 Total revenues from contract and other collaboration — 60 Total revenue $ 442 $ 511
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at January 1, 2022 $ 1,237 Deductions for performance obligations satisfied: In current period — Balance at March 31, 2022 $ 1,237 Balance at January 1, 2021 $ 49 Deductions for performance obligations satisfied: In current period (49 ) Balance at March 31, 2021 $ —

Note 7 - Leases (Tables)

Note 7 - Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Lease, Cost [Table Text Block]	Three Months Ended March 31, 2022 2021 Operating lease costs $ 343 $ 340 Gain on derecognition of operating lease — (522 ) Sublease income — (150 ) Net lease costs $ 343 $ (332 ) March 31, 2022 March 31, 2021 Weighted-average remaining lease term – operating leases (in years) 4.74 0.57 Weighted-average remaining discount rate – operating leases 12.8 % 12.03 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year: 2022 $ 1,363 2023 1,294 2024 1,040 2025 1,040 2026 1,040 Thereafter 415 Total future minimum lease payments 6,192 Less imputed interest (1,430 ) Total $ 4,762 Operating lease liabilities $ 4,762 Operating lease liabilities, current portion (1,184 ) Operating lease liabilities, net of current portion $ 3,578

Note 8 - Liability Related to_2

Note 8 - Liability Related to Sale of Future Royalties (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Other Liabilities [Table Text Block]	Three months ended March 31, 2022 Period from inception to March 31, 2022 Liability related to sale of future royalties — beginning balance $ 85,288 $ — Proceeds from sale of future royalties — 61,184 Non-cash royalty revenue — (1,083 ) Non-cash interest (income) expense recognized (673 ) 24,514 Liability related to sale of future royalties as of March 31, 2022 $ 84,615 $ 84,615

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	March 31, 2022 March 31, 2021 Cost of goods sold $ 19 $ 22 Research and development 174 181 Selling, general and administrative 590 886 Total $ 783 $ 1,089
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Number of Average Restricted Grant Date Stock Units Fair Value Restricted stock units outstanding, January 1, 2022 1,774,376 $ 1.71 Granted 1,061,826 0.40 Vested (657,359 ) 1.92 Forfeited (145,838 ) 1.56 Restricted stock units outstanding, March 31, 2022 2,033,005 $ 0.97
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Number of Stock Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (in thousands) January 1, 2022 14,284,050 $ 2.99 Granted 2,123,650 0.40 Forfeited (248,334 ) 1.72 Expired (517,902 ) 3.20 Exercised — — March 31, 2022 15,641,464 $ 2.65 6.2 $ — Vested and exercisable options—March 31, 2022 10,426,287 $ 3.36 4.8 $ — Vested and expected to vest—March 31, 2022 15,641,464 $ 2.65 6.2 $ —
Performance Shares [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three months ended March 31, 2022 Expected term (in years) 6.3 Risk-free interest rate 1.6% - 2.2% Expected volatility 88% Expected dividend rate 0%

Note 11 - Net Loss Per Share _2

Note 11 - Net Loss Per Share of Common Stock (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2022 2021 ESPP, RSUs and stock options to purchase common stock 17,864,469 16,789,212 Common stock warrants 17,676,679 176,679

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Cash, Cash Equivalents, and Short-Term Investments, Total	$ 39,349	$ 51,630

Note 2 - Investments and Fair_3

Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale	$ 0		$ 0
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total	0	$ 0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3	$ 0		$ 0

Note 2 - Investments and Fair_4

Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Gross Unrealized Gains	$ 0	$ 0
Gross Unrealized Losses	0	0
Cash and cash equivalents	21,822	12,663	[1]
Total cash, cash equivalents and short-term investments	39,349	51,630
Total cash, cash equivalents and short-term investments, fair value	39,349	51,630
Cash and Cash Equivalents [Member]
Cash and cash equivalent, fair value	21,822	12,663
Cash and cash equivalents	21,822	12,663
Cash and Cash Equivalents [Member] | Cash [Member]
Cash, amortized cost	2,621	1,443
Cash and cash equivalent, fair value	2,621	1,443
Cash and Cash Equivalents [Member] | Money Market Funds [Member]
Cash and cash equivalent, fair value	562	2,822
Money market funds, amortized cost	562	2,822
Cash and Cash Equivalents [Member] | Commercial Paper [Member]
Short-term investment, amortized Cost	18,639	8,398
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	18,639	8,398
Marketable Securities [Member]
Short-term investment, amortized Cost	17,527	38,967
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	17,527	38,967
Marketable Securities [Member] | Commercial Paper [Member]
Short-term investment, amortized Cost	13,557	29,504
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	13,557	29,504
Marketable Securities [Member] | Corporate Debt Securities [Member]
Short-term investment, amortized Cost	3,970	9,463
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Short-term investment, fair value	$ 3,970	$ 9,463
[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 2 - Investments and Fair_5

Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets, fair value	$ 36,728	$ 50,187
Liabilities, fair value	55	81
Contingent Put Option Liability [Member]
Liabilities, fair value	55	81
Fair Value, Inputs, Level 1 [Member]
Assets, fair value	562	2,822
Liabilities, fair value	0	0
Fair Value, Inputs, Level 1 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Assets, fair value	36,166	47,365
Liabilities, fair value	0	0
Fair Value, Inputs, Level 2 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Liabilities, fair value	55	81
Fair Value, Inputs, Level 3 [Member] | Contingent Put Option Liability [Member]
Liabilities, fair value	55	81
Money Market Funds [Member]
Assets, fair value	562	2,822
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	562	2,822
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	0	0
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Commercial Paper [Member]
Assets, fair value	32,196	37,902
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	32,196	37,902
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	0	0
Corporate Debt Securities [Member]
Assets, fair value	3,970	9,463
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets, fair value	0	0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets, fair value	3,970	9,463
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets, fair value	$ 0	$ 0

Note 2 - Investments and Fair_6

Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair value, Beginning of period	$ 81	$ 246
Change in fair value of contingent put option associated with the Loan Agreement	(26)
Change in fair value of contingent put option associated with the Loan Agreement		(65)
Fair value, End of period	$ 55	$ 181

Note 3 - Inventories, Net (Deta

Note 3 - Inventories, Net (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
ZALVISO [Member]
Inventory Write-down	$ 0	$ 100

Note 3 - Inventories, Net - Inv

Note 3 - Inventories, Net - Inventory Components (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Raw materials	$ 651	$ 722
Work-in-process	35	159
Finished goods	359	230
Total	$ 1,045	$ 1,111	[1]
[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 4 - Asset Acquisition (Det

Note 4 - Asset Acquisition (Details Textual) - Lowell Therapeutics [Member] $ / shares in Units, $ in Thousands	Jan. 07, 2022USD ($)$ / sharesshares
Business Combination, Consideration Transferred, Net of Cash Acquired	$ 32,500
Cash Acquired from Acquisition	3,549
Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash	$ 3,500
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares) | shares	1,396,526
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value	$ 800	[1]
Business Combination, Cash and Stock Paid for Transaction Costs	500
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total	8,819	[2]
Business Combination, Consideration Transferred, Total	12,368
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	6,000
Business Combination, Acquisition Related Costs	500
Payments to Acquire Businesses, Gross	3,536
Business Acquisition, Transaction Costs	2,521
Contingent Consideration Payable Upon Achievement of Milestones [Member]
Business Combination, Contingent Consideration, Liability, Total	$ 26,000
AcelRx Common Stock [Member]
Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares) | shares	9,009,538
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share) | $ / shares	$ 0.57284
Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Value	$ 5,200
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares) | shares	1,396,526
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value	$ 800
[1]	Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.
[2]	Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.

Note 4 - Asset Acquisition - Co

Note 4 - Asset Acquisition - Consideration for Acquisition (Details) - Lowell Therapeutics [Member] $ in Thousands	Jan. 07, 2022USD ($)
Payments to Acquire Businesses, Gross	$ 3,536
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	6,000
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Value	800	[1]
Business Acquisition, Transaction Costs	2,521
Business Combination, Consideration Transferred, Total	12,368
Cash acquired	(3,549)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total	8,819	[2]
Common Stock [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	5,161
Common Stock to Settle Transaction Costs [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	$ 350
[1]	Recorded as Other long-term liabilities in the Condensed Consolidated Balance Sheets.
[2]	Recorded as In-process research and development asset in the Condensed Consolidated Balance Sheets.

Note 4 - Asset Acquisition - _2

Note 4 - Asset Acquisition - Consideration for Acquisition (Details) (Parentheticals)	Jan. 07, 2022shares
Lowell Therapeutics [Member]
Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)	1,396,526

Note 5 - Revenue From Contrac_3

Note 5 - Revenue From Contracts With Customers (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Contract with Customer, Liability, Total	$ 1,237	$ 1,237	$ 0	$ 49
DZUVEO [Member] | Aguettant [Member]
Contract with Customer, Liability, Total	1,200
Contract with Customer, Liability, Current	$ 100

Note 5 - Revenue From Contrac_4

Note 5 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenue	$ 442	$ 511
DSUVIA [Member]
Revenue	442	181
ZALVISO [Member]
Revenue	0	270
Product [Member]
Revenue	442	451
Non-cash Royalty [Member]
Revenue	0	45
Royalty [Member]
Revenue	0	15
Contract and Other Collaboration [Member]
Revenue	$ 0	$ 60

Note 5 - Revenue From Contrac_5

Note 5 - Revenue From Contracts With Customers - Contract Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Balance	$ 1,237	$ 49
In current period	0	(49)
Balance	$ 1,237	$ 0

Note 6 - Long-term Debt (Detail

Note 6 - Long-term Debt (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 01, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	May 30, 2019
Amortization of Debt Discount (Premium)		$ 134	$ 222
Leasehold Improvements, Gross				$ 1,700
Site Readiness Agreement [Member]
Debt Instrument, Periodic Payment, Principal	$ 500
Total Obligation Under Leasehold Agreement				500
Debt Instrument, Interest Rate, Effective Percentage		14.40%
Warrant In Connection with Oxford Finance Loan Agreement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					176,679
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 2.83
Loan Agreement with Oxford Finance LLC [Member]
Debt Instrument, Face Amount					$ 25,000
Long-Term Debt, Total		$ 11,400		$ 13,300
Interest Expense, Debt, Total		400	600
Amortization of Debt Discount (Premium)		$ 100	$ 200

Note 7 - Leases (Details Textua

Note 7 - Leases (Details Textual) - USD ($)	Mar. 26, 2021	Mar. 31, 2022	Dec. 31, 2021	[1]
Operating Lease, Right-of-Use Asset		$ 4,147,000	$ 4,302,000
Lease for Corporate Headquarters in Hayward, California [Member]
Lessee, Operating Lease, Term of Contract (Year)	2 years 3 months
Lessee, Operating Lease, Monthly Rent	$ 17,000
Lessee, Operating Lease, Abated Rent Period (Month)	1 month
Operating Lease, Right-of-Use Asset	$ 400,000
[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 7 - Leases - Operating Lea

Note 7 - Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating lease costs	$ 343	$ 340
Gain on lease termination	0	(522)
Sublease income	0	(150)
Net lease costs	$ 343	$ (332)
Weighted-average remaining lease term – operating leases (in years) (Year)	4 years 8 months 26 days	6 months 25 days
Weighted-average remaining discount rate – operating leases	12.80%	12.03%

Note 7 - Leases - Maturities of

Note 7 - Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	[1]
2022	$ 1,363
2023	1,294
2024	1,040
2025	1,040
2026	1,040
Thereafter	415
Total future minimum lease payments	6,192
Less imputed interest	(1,430)
Total	4,762
Operating lease liabilities	4,762
Operating lease liabilities, current portion	(1,184)	$ (1,068)
Operating lease liabilities, net of current portion	$ 3,578	$ 3,750
[1]	The condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Note 8 - Liability Related to_3

Note 8 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($) $ in Millions	Sep. 18, 2015	Mar. 31, 2022	Mar. 31, 2021
Proceeds From Sale of Royalty and Milestone Rights	$ 65
Contingent Gain (Loss) on Royalty Monetization Arrangement		$ 64
Effective Interest Over Life of Liability Related to Sale of Future Royalties		0.00%
Effective Annual Interest Rate		3.20%	3.60%
SWK [Member]
Percentage of Royalties and Rights Under Agreement	75.00%
SWK [Member] | First Four Commercial Milestones [Member]
Percentage of Royalties and Rights Under Agreement	80.00%
Commercial Milestones Value Maximum Amount Available	$ 35.6
AcelRX [Member] | First Four Commercial Milestones [Member]
Commercial Milestones Value Maximum Amount Available	$ 44.5

Note 8 - Liability Related to_4

Note 8 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands	3 Months Ended		78 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022
Liability related to sale of future royalties — beginning balance	$ 85,288		$ 0
Proceeds from sale of future royalties	0		61,184
Non-cash royalty revenue	0		(1,083)
Non-cash interest (income) expense recognized	(673)	$ (782)	24,514
Liability related to sale of future royalties as of March 31, 2022	$ 84,615		$ 84,615

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual)	Jul. 06, 2021	Jun. 08, 2021
Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]
Loss Contingency, Number of Defendants		2
Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]
Loss Contingency, Number of Defendants	10

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation (Details Textual)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 0.30
The 2020 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	5,585,531
Amended ESPP [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	4,302,929
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)	141,966

Note 10 - Stock Based Compensat

Note 10 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Stock-based compensation expense	$ 783	$ 1,089
Cost of Sales [Member]
Stock-based compensation expense	19	22
Research and Development Expense [Member]
Stock-based compensation expense	174	181
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 590	$ 886

Note 10 - Stock Based Compens_2

Note 10 - Stock Based Compensation - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Restricted stock units outstanding (in shares) | shares	1,774,376
Restricted stock units weighted average outstanding (in dollars per share) | $ / shares	$ 1.71
Granted (in shares) | shares	1,061,826
Weighted average grant date fair value, granted (in dollars per share) | $ / shares	$ 0.40
Vested (in shares) | shares	(657,359)
Weighted average grant date fair value, vested (in dollars per share) | $ / shares	$ 1.92
Forfeited (in shares) | shares	(145,838)
Weighted average grant date fair value, forfeited (in dollars per share) | $ / shares	$ 1.56
Restricted stock units outstanding (in shares) | shares	2,033,005
Restricted stock units weighted average outstanding (in dollars per share) | $ / shares	$ 0.97

Note 10- Stock Based Compensati

Note 10- Stock Based Compensation - Option Activity (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares
Outstanding (in shares) | shares	14,284,050
Outstanding (in dollars per share) | $ / shares	$ 2.99
Granted (in shares) | shares	2,123,650
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.40
Forfeited (in shares) | shares	(248,334)
Forfeited, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.72
Expired (in shares) | shares	(517,902)
Expired, weighted-average exercise price (in dollars per share) | $ / shares	$ 3.20
Exercised (in shares) | shares	0
Exercised, weighted-average exercise price (in dollars per share) | $ / shares	$ 0
Outstanding (in shares) | shares	15,641,464
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 2.65
Outstanding, weighted-average remaining contractual life (Year)	6 years 2 months 12 days
Outstanding, aggregate intrinsic value | $	$ 0
Vested and exercisable options (in shares) | shares	10,426,287
Vested and exercisable options, weighted-average exercise price (in dollars per share) | $ / shares	$ 3.36
Vested and exercisable options, weighted-average remaining contractual life (Year)	4 years 9 months 18 days
Vested and exercisable options, aggregate intrinsic value | $	$ 0
Vested and expected to vest (in shares) | shares	15,641,464
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares	$ 2.65
Vested and expected to vest, weighted-average remaining contractual life (Year)	6 years 2 months 12 days
Vested and expected to vest, aggregate intrinsic value | $	$ 0

Note 10 - Stock Based Compens_3

Note 10 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details) - Performance Shares [Member]	3 Months Ended
	Mar. 31, 2022
Expected term (in years) (Year)	6 years 3 months 18 days
Expected volatility	88.00%
Expected dividend rate	0.00%
Minimum [Member]
Risk-free interest rate	1.60%
Maximum [Member]
Risk-free interest rate	2.20%

Note 11 - Net Loss Per Share _3

Note 11 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
RSU's, ESPP, and Employee Stock Options [Member]
Antidilutive securities (in shares)	17,864,469	16,789,212
Warrant [Member]
Antidilutive securities (in shares)	17,676,679	176,679

Note 12 - Subsequent Event (Det

Note 12 - Subsequent Event (Details Textual) - Forecast [Member] - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	May 31, 2022	Jun. 30, 2022
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent	40.00%
Severance Costs		$ 0.5